Literature DB >> 12621243

Reversible posterior leukoencephalopathy syndrome in children with cancers.

Aiko Suminoe1, Akinobu Matsuzaki, Ryutaro Kira, Nami Fukunaga, Toshinori Nishio, Takayuki Hoshina, Toshiro Hara.   

Abstract

We report three cases of reversible posterior leukoencephalopathy syndrome (RPLS) in children with cancers. All patients presented with sudden confusional state, visual disturbance, and transient mild hypertension under the treatment of childhood cancers. Magnetic resonance imaging of the brain demonstrated cortical and subcortical lesions predominantly in the occipital region, which showed high intensity signal on fluid-attenuated inversion recovery images. All patients completely recovered from their neuropsychologic deficits only with antihypertensive therapy or discontinuation of the possible offending drugs. Early recognition of RPLS as a complication during cancer therapy in childhood may facilitate precise diagnosis and appropriate treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621243     DOI: 10.1097/00043426-200303000-00010

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Reversible posterior leucoencephalopathy syndrome: a cause of temporary cortical blindness.

Authors:  N Niyadurupola; C A M Burnett; L E Allen
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

2.  Tumor lysis syndrome as a risk factor for posterior reversible encephalopathy syndrome in children with hematological malignancies.

Authors:  Daisuke Suzuki; Ryoji Kobayashi; Akihiro Iguchi; Hirozumi Sano; Kenji Kishimoto; Kazue Yasuda; Kunihiko Kobayashi
Journal:  Int J Hematol       Date:  2014-09-13       Impact factor: 2.490

3.  Posterior Reversible Encephalopathy Syndrome in Pediatric Cancer: Clinical and Radiologic Findings.

Authors:  Saadiya Javed Khan; Arjumand Ali Arshad; Mohammad Bilal Fayyaz; Islah Ud Din Mirza
Journal:  J Glob Oncol       Date:  2017-12-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.